Allena Pharmaceuticals Inc (NASDAQ:ALNA) – Equities research analysts at B. Riley lifted their Q2 2020 earnings per share estimates for Allena Pharmaceuticals in a research note issued to investors on Wednesday, March 18th. B. Riley analyst M. Mamtani now anticipates that the company will earn ($0.18) per share for the quarter, up from their prior forecast of ($0.22). B. Riley currently has a “Buy” rating and a $7.00 target price on the stock. B. Riley also issued estimates for Allena Pharmaceuticals’ Q3 2020 earnings at ($0.18) EPS, Q4 2020 earnings at ($0.18) EPS, FY2020 earnings at ($0.85) EPS, FY2021 earnings at ($0.48) EPS, FY2022 earnings at ($0.37) EPS, FY2023 earnings at ($0.21) EPS and FY2024 earnings at ($0.06) EPS.
ALNA has been the subject of a number of other research reports. Credit Suisse Group reaffirmed a “hold” rating and set a $4.00 target price on shares of Allena Pharmaceuticals in a report on Monday, February 17th. Roth Capital decreased their target price on Allena Pharmaceuticals from to in a report on Wednesday, March 18th. Wedbush reaffirmed a “buy” rating and set a $26.00 target price on shares of Allena Pharmaceuticals in a report on Wednesday, February 12th. Finally, Zacks Investment Research raised Allena Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 target price for the company in a report on Wednesday, March 18th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $9.75.
Allena Pharmaceuticals stock opened at $0.90 on Monday. The company has a quick ratio of 3.96, a current ratio of 3.03 and a debt-to-equity ratio of 0.35. Allena Pharmaceuticals has a 52 week low of $0.52 and a 52 week high of $7.31. The company has a market capitalization of $23.41 million, a price-to-earnings ratio of -0.42 and a beta of 1.80. The stock has a 50-day moving average price of $1.97 and a 200 day moving average price of $2.96.
Allena Pharmaceuticals (NASDAQ:ALNA) last issued its quarterly earnings results on Monday, March 16th. The company reported ($0.47) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.52) by $0.05.
Several institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its holdings in shares of Allena Pharmaceuticals by 103.0% during the fourth quarter. Geode Capital Management LLC now owns 105,854 shares of the company’s stock worth $288,000 after purchasing an additional 53,719 shares during the period. Algert Global LLC acquired a new stake in shares of Allena Pharmaceuticals during the fourth quarter worth about $101,000. Banco Bilbao Vizcaya Argentaria S.A. acquired a new stake in shares of Allena Pharmaceuticals during the fourth quarter worth about $104,000. Renaissance Technologies LLC lifted its holdings in shares of Allena Pharmaceuticals by 91.2% during the fourth quarter. Renaissance Technologies LLC now owns 241,700 shares of the company’s stock worth $660,000 after purchasing an additional 115,300 shares during the period. Finally, Wedbush Securities Inc. lifted its holdings in shares of Allena Pharmaceuticals by 95.5% during the fourth quarter. Wedbush Securities Inc. now owns 50,150 shares of the company’s stock worth $137,000 after purchasing an additional 24,500 shares during the period. 61.61% of the stock is owned by hedge funds and other institutional investors.
Allena Pharmaceuticals Company Profile
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company’s lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.